Last reviewed · How we verify
Standard dose influenza vaccination
Standard dose influenza vaccination is a vaccine Biologic drug developed by University of Miami. It is currently FDA-approved for Seasonal influenza prevention in adults and children ≥6 months of age. Also known as: Fluzone quadrivalent.
Influenza vaccination stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains.
Influenza vaccination stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains. Used for Seasonal influenza prevention in adults and children ≥6 months of age.
At a glance
| Generic name | Standard dose influenza vaccination |
|---|---|
| Also known as | Fluzone quadrivalent |
| Sponsor | University of Miami |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated or attenuated influenza virus antigens that trigger both humoral (antibody) and cell-mediated immune responses. This prepares the immune system to recognize and rapidly neutralize influenza viruses upon natural exposure, reducing infection risk and disease severity. The standard dose formulation is designed to provide optimal immunogenicity in the general adult population.
Approved indications
- Seasonal influenza prevention in adults and children ≥6 months of age
Common side effects
- Injection site soreness, redness, or swelling
- Myalgia (muscle aches)
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients (PHASE2)
- Open-Label Influenza Vaccine Evaluation (NA)
- High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients (PHASE2)
- Effect of Influenza Vaccination on Global Systemic Inflammatory Markers in Patients With Stable Coronary Artery Disease (PHASE4)
- High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater) (PHASE2)
- A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision (EARLY_PHASE1)
- A Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in Older Adults (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard dose influenza vaccination CI brief — competitive landscape report
- Standard dose influenza vaccination updates RSS · CI watch RSS
- University of Miami portfolio CI
Frequently asked questions about Standard dose influenza vaccination
What is Standard dose influenza vaccination?
How does Standard dose influenza vaccination work?
What is Standard dose influenza vaccination used for?
Who makes Standard dose influenza vaccination?
Is Standard dose influenza vaccination also known as anything else?
What drug class is Standard dose influenza vaccination in?
What development phase is Standard dose influenza vaccination in?
What are the side effects of Standard dose influenza vaccination?
Related
- Drug class: All vaccine drugs
- Manufacturer: University of Miami — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Seasonal influenza prevention in adults and children ≥6 months of age
- Also known as: Fluzone quadrivalent
- Compare: Standard dose influenza vaccination vs similar drugs
- Pricing: Standard dose influenza vaccination cost, discount & access